Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinical development, CT-0508.
Carisma通知Novartis藥品公司其終止製造和供應協議，該協議日期爲2023年3月1日，涉及首個進入臨床開發的產品候選製造CT-0508。
The termination is effective July 31, 2024. Pursuant to the Company's revised operating plan, the Company determined to focus its ex vivo oncology clinical development efforts on its follow-on product candidate CT-0525 and has suspended enrollment of new patients in its Phase 1 clinical trial for CT-0508.
終止日期爲2024年7月31日。根據公司修訂的運營計劃，公司決定將重點放在其後續產品候選CT-0525的腫瘤臨床開發上，並暫停招募CT-0508的一期臨床試驗的新患者。體外由於製造協議的終止，公司將承擔等於400萬美元的終止費用，預計將於2024年第三季度支付。
As a result of the termination of the Manufacturing Agreement, the Company will incur a termination fee equal to $4.0 million, which is expected to be paid in the third quarter of 2024.
由於製造協議的終止，公司將承擔等於4.0百萬美元的終止費用，預計將於2024年第三季度支付。
譯文內容由第三人軟體翻譯。